Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173048 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL29125008 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2744005 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL30954764 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL203262 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19172281 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23015072 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2786532 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1008189 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1009635 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902399-B2 | Fatty acids analogous | THIA MEDICA AS (NO) | 2011-03-08 | — | — | US | claimed |
| US-12397058-B2 | Metabolically stable prodrugs | TSRL, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240368410-A1 | SELECTIVE SELF-ASSEMBLED MONOLAYERS VIA SPIN-COATING METHOD FOR USE IN DSA | MERCK PATENT GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| US-12019075-B2 | Zwitterionic nanoparticles | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2024-06-25 | — | — | US | disclosed |
| CN-117957209-A | Selective self-assembled monolayers for DSA via spin coating | 默克专利股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-116496289-A | Synthesis and application of membrane-targeted naphthalene endoperoxides | 大连理工大学 | 2023-07-28 | — | — | CN | disclosed |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2023-05-25 | — | — | US | disclosed |
| US-11299572-B2 | Block copolymer | LG CHEM, LTD. | 2022-04-12 | — | — | US | disclosed |
| EP-0595796-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993010741-A2 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1993-06-10 | — | — | WO | disclosed |
| US-5204337-A | Estrogen nucleus derivatives for use in inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| EP-0485392-A1 | ANDROGEN DERIVATIVES FOR USE IN THE INHIBITION OF SEX STEROID ACTIVITY | ENDORECHERCHE INC. (CA) | 1992-05-20 | — | — | EP | disclosed |
| EP-0480950-A1 | COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ENDORECHERCHE INC. (CA) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991000731-A1 | COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | disclosed |
| WO-1991000733-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | disclosed |
| WO-1991000732-A1 | ANDROGEN DERIVATIVES FOR USE IN THE INHIBITION OF SEX STEROID ACTIVITY | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | disclosed |
| EP-0367576-A2 | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1990-05-09 | — | — | EP | disclosed |
| US-4243660-A | 11-HEXADECENYL AND 11-HEPTADECENYL ACETATE; SYNERGISTIC | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12019075-B2 | Zwitterionic nanoparticles | ANXA3, ANXA5, ANXA11 | MEN1 462/4885KMT2A 3627/4885KDM4C 4315/4885 |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | ANXA3, ANXA5, ANXA11 | MEN1 846/4885KMT2A 3703/4885KDM4C 3902/4885 |
| US-12397058-B2 | Metabolically stable prodrugs | CES1, CES2, CYP2S1 | MEN1 1968/4885KMT2A 3952/4885KDM4C 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.